220 related articles for article (PubMed ID: 38099939)
1. Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions.
Lin S; Lei S; Liu W; Zhu X; Ren B; Feng B
Eur J Clin Pharmacol; 2024 Feb; 80(2):249-259. PubMed ID: 38099939
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
[TBL] [Abstract][Full Text] [Related]
4. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
[TBL] [Abstract][Full Text] [Related]
5. Time series analysis of using the PDCA method combined with the Teach-back method to improve spontaneous reports of adverse drug reactions in a grade IIIA hospital in China.
Li B; Jiang L; Liao L; Chen Y; Xu Z; Wu N; Chen H; Wu P; Liu T
Eur J Clin Pharmacol; 2024 Mar; 80(3):383-393. PubMed ID: 38151504
[TBL] [Abstract][Full Text] [Related]
6. Current Scenario and Future Prospects of Adverse Drug Reactions (ADRs) Monitoring and Reporting Mechanisms in the Rural Areas of India.
Shukla S; Sharma P; Gupta P; Pandey S; Agrawal R; Rathour D; Kumar Kewat D; Singh R; Kumar Thakur S; Paliwal R; Sulakhiya K
Curr Drug Saf; 2024; 19(2):172-190. PubMed ID: 37132145
[TBL] [Abstract][Full Text] [Related]
7. The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015).
Almutairi KB; Inderjeeth CA; Preen DB; Keen HI; Nossent JC
Rheumatol Int; 2024 Jun; 44(6):1089-1099. PubMed ID: 38615313
[TBL] [Abstract][Full Text] [Related]
8. Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database.
Gustafsson M; Matos C; Joaquim J; Scholl J; van Hunsel F
Drug Saf; 2023 Nov; 46(11):1133-1148. PubMed ID: 37824028
[TBL] [Abstract][Full Text] [Related]
9. A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues.
Hasford J; Bruchmann F; Lutz M; Thürmann P; Schmiedl S
Eur J Clin Pharmacol; 2021 Nov; 77(11):1697-1704. PubMed ID: 34143228
[TBL] [Abstract][Full Text] [Related]
10. Patterns of adverse drug reactions in Jordan: a retrospective analysis of the National Pharmacovigilance Data Registry (2015-2021).
Mhaidat NM; Alshogran OY; Altawalbeh SM; Jaber JM; Banat HA; Ahmad DS; Alabsi W
Expert Opin Drug Saf; 2023; 22(10):957-965. PubMed ID: 37293991
[TBL] [Abstract][Full Text] [Related]
11. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
[TBL] [Abstract][Full Text] [Related]
13. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
[TBL] [Abstract][Full Text] [Related]
14. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
15. Monitoring drug safety in Astrakhan, Russia.
Kirilochev OO; Dorfman IP; Umerova AR
Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
[TBL] [Abstract][Full Text] [Related]
16. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
Wang G; Wang J; Du R; Wang Y; Li Z
Paediatr Drugs; 2024 Mar; 26(2):175-185. PubMed ID: 38153627
[TBL] [Abstract][Full Text] [Related]
17. Mining Real-World Big Data to Characterize Adverse Drug Reaction Quantitatively: Mixed Methods Study.
Yue QX; Ding RF; Chen WH; Wu LY; Liu K; Ji ZL
J Med Internet Res; 2024 May; 26():e48572. PubMed ID: 38700923
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
[TBL] [Abstract][Full Text] [Related]
19. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
[TBL] [Abstract][Full Text] [Related]
20. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
